What happened with SI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Shoulder Innovations focuses exclusively on shoulder surgery and currently sells only in the United States. Hospitals and ambulatory surgery centers buy its implants for shoulder replacement procedures, generating the company’s revenue. Its systems cover both anatomic and reverse shoulder replacement and include its proprietary InSet Glenoid implant, which fits within a rim of the patient’s existing bone.
The company targets high-volume shoulder surgeons through its commercial teams and independent distributors. It supports them with ProVoyance preoperative planning, training and help during procedures. Sales depend on surgeons choosing its systems and facilities approving their use and purchase. Those facilities generally rely on government and private insurers to reimburse procedure and product costs.
Shoulder Innovations outsources manufacturing and relies on single sources for many components, including Avalign Technologies for humeral stems and Micropulse for InSet Glenoid products. Its commercial devices have FDA clearance, but it may promote them only for authorized uses; new devices and some modifications require further authorization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Shoulder Innovations depends on shoulder replacement volumes and surgeon adoption; important rivals Arthrex and Exactech are also worth watching, though neither appears in this list.
Enovis sells joint replacement implants and competes directly for the shoulder operations that Shoulder Innovations serves. Watch its Reconstructive business rather than its non-surgical recovery products, while remembering that this business also covers other joints, limb reconstruction, and foot and ankle procedures.
Zimmer Biomet and Shoulder Innovations compete to supply shoulder replacement implants to orthopedic surgeons and surgical facilities. Watch Zimmer Biomet’s new implant products and improvements: it identifies technology, quality, service and pricing as key factors in winning orthopedic customers.
Stryker competes with Shoulder Innovations to sell shoulder replacement systems to surgeons and surgical facilities. Its Orthopaedics sales are the closer comparison, but that segment accounted for only 38% of Stryker’s net sales in 2025, so company-wide growth is not a focused measure of shoulder demand.
Smith & Nephew competes with Shoulder Innovations for shoulder replacement surgeons and their implant purchases. Its medical education and clinical evidence supporting product marketing are worth watching as ways it supports surgeons’ product use and builds customer relationships.
Johnson & Johnson competes with Shoulder Innovations in shoulder replacement, but its overall results are a less focused comparison. It also sells prescription medicines to retailers, wholesalers, distributors, hospitals and healthcare professionals, so its broader pharmaceutical business makes shoulder competition harder to read from the company totals.
Fed Interest Rate Decision
Shoulder Innovations’ $15 million loan costs more when increases in the Fed’s policy rate feed through to prime above the loan’s 11.00% floor, leaving less cash for its shoulder implant business.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest costs on the loan if its rate is above the floor, leaving less cash for implant sales, surgeon support and business expansion.
If it comes in below expectations
Lower rates can reduce interest costs if the loan rate is above the floor, leaving more cash for implant sales, surgeon support and business expansion.
Zimmer Biomet Holdings, Inc. earningsZBH
Zimmer Biomet's report will show how its shoulder implants and product improvements compete for the same surgeons and facilities as Shoulder Innovations.
Look first for shoulder-specific results, then for comments on new implants, quality, service and pricing. Stronger shoulder results alongside signs that product improvements are gaining use would suggest Zimmer Biomet is drawing more strongly on the surgeons and facilities both companies seek, raising the competitive pressure on Shoulder Innovations; shoulder-specific weakness could ease that pressure. If Zimmer reports only broader orthopedic results that include other businesses, those results cannot establish a change in shoulder demand or competition. The conclusion is whether Zimmer is gaining or losing pull with the customers the companies share.
Shoulder Innovations, Inc. earningsThis company
Shoulder Innovations' report will show whether surgeons and facilities are using more of its shoulder implant systems and turning those procedures into sales.
Read implant systems sold alongside revenue, then check gross margin—the share of sales left after implant costs. Rising systems and revenue with a steady margin would show broader use without a clear loss of cost room; weaker sales or a falling margin would point to slower adoption or less favorable economics per procedure. The question is whether growth is also translating into sounder product economics.
